Influenza virus neuraminidase and internal viral proteins (NA and internal proteins)

Influenza virus neuraminidase (NA) and internal viral proteins, including nucleoprotein (NP) and matrix proteins (M1, M2), constitute the primary antigenic components of whole-virion inactivated vaccines such as Fluval P and Fluval AB (Omninvest/Fluart). Neuraminidase is a surface enzyme that facilitates the release of progeny viruses from infected host cells by cleaving terminal sialic acid residues from cell-surface glycoproteins (PubMed: 22226115). The internal proteins, particularly NP and M1, are highly conserved across influenza strains and are critical for viral RNA packaging, structural integrity, and replication (UniProt: P03466). While NA is the direct target of clinical antivirals like oseltamivir and zanamivir, the internal proteins are vital for inducing broad-spectrum T-cell responses that can provide cross-protection against heterologous influenza strains (PubMed: 21148215). This target entry is classified as incorrect because it represents a complex mixture of multiple distinct viral proteins used in specific vaccine formulations rather than a single molecular therapeutic target.

Other names

NeuraminidaseSialidaseNucleoproteinMatrix protein M1Matrix protein M2RNA-directed RNA polymerase catalytic subunitFluval vaccine antigens

Neuraminidase inhibitors (e.g., oseltamivir) block the cleavage of sialic acid, preventing the release of new virions. M2 inhibitors (e.g., amantadine) block the ion channel required for viral uncoating. Polymerase inhibitors (e.g., baloxavir) inhibit the cap-snatching mechanism of viral mRNA synthesis. In vaccines like Fluval P and Fluval AB, these proteins act as antigens to induce neutralizing antibodies and T-cell mediated immunity.